Oculis Holding AG announced that Professor Ramin Tadayoni, M.D., Ph.D., presented the positive results from Stage 1 of the Phase 3 DIAMOND trial of OCS-01 in patients with DME at the 23rd EURETINA congress, which took place October 5-8, 2023 in Amsterdam, the Netherlands. Professor Tadayoni, who also chaired the "Landmarks and Late Breakings" session, presented data from the Stage 1 of the DIAMOND Phase 3 program showing that the trial met primary and secondary endpoints with robust statistical significance, and achieved its objective of confirming the loading and maintenance dose to be tested in Stage 2 of the trial. Specifically, the trial met its primary endpoint, showing a statistically significant improvement in Best Corrected Visual Acuity (BCVA) in patients treated with OCS-01versus vehicle-treated patients at Week 6 (OCS-01: 7.2 letters vs vehicle: 3.1 letters, p=0.007), which was sustained through Week 12 (OCS-01:7.6 letters vs vehicle: 3.7 letters, p=0.016).

For two secondary endpoints, a significantly higher percentage of patients treated with OCS-1 achieved 15- letter improvement in BCVA (OCS-01 25.3% vs vehicle: 9.8%, p= 0.015), and patients in the OCS-01 treatment arm also showed significant improvement in retinal thickness as compared to vehicle (OCS-01: -63.6 um vs vehicle: +5.5 um, pRamin Tadayoni, M., Ph.D., Professor of Ophthalmology, Universite Paris Cite, France, and Department Head at Lariboisiere, Saint Louis and Adolphe de Rothschild Foundation hospitals, and Co-chair of Oculis' Scientific Advisory Board, commented: "The results from the DIAMOND Phase 3 Stage 1 trial are exciting and very meaningful for both clinicians and patients with DME, the leading cause of visual loss and legal blindness in patients with diabetes. The Company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.